Food and drug administration

Chemokine

Multiple myeloma

Transplantation

Receptor

CXCR4

Plerixafor

Bone marrow

Drug

Immunology

Liver transplantation

Lymphoma

Internal medicine

Pharmacology

Hepatopulmonary syndrome

Oncology

Medicine

Antiviral chemistry & chemotherapy

AMD3100 (plerixafor, Mozobil®) was first identified as an anti-HIV agent specifically active against the T4-lymphotropic HIV strains, as it selectively blocked the CXCR4 receptor. Through interference with the interaction of CXCR4 with its natural ligand, SDF-1 (also named CXCL12), it also mobilized the CD34 + stem cells from the bone marrow into the peripheral blood stream. In December 2008, AMD3100 was formally approved by the US FDA for autologous transplantation in patients with Non-Hodgkin’s Lymphoma or multiple myeloma. It may be beneficially used in various other malignant diseases as well as hereditary immunological disorders such as WHIM syndrome, and physiopathological processes such as hepatopulmonary syndrome.

Mozobil® (Plerixafor, AMD3100), 10 years after its approval by the US Food and Drug Administration